Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease.

Tal MarshanskiEliana FanousNoa TalTsachi T PeretsManar MatarYael WeintraubRaanan ShamirDror S Shouval

Published in: Journal of pediatric gastroenterology and nutrition (2024)

Accelerated infliximab dosing during induction did not result in improved outcomes up to 12 months follow-up. Prospective studies are required to determine the exact timing in which proactive TDM should be applied.

Keyphrases

ulcerative colitis
young adults
density functional theory
disease activity
type diabetes
metabolic syndrome
rheumatoid arthritis
systemic lupus erythematosus
adipose tissue
insulin resistance